The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants-Reference-Cited by-同舟云学术

The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants

Published:2024-04-08 Issue: Volume: Page:1-8
ISSN:1478-7210
Container-title:Expert Review of Anti-infective Therapy
language:en
Short-container-title:Expert Review of Anti-infective Therapy

Author:

Hsu Chi-Kuei¹²,Hsu Wan-Hsuan³^ORCID,Shiau Bo-Wen⁴,Tsai Ya-Wen⁵⁶,Wu Jheng-Yan⁷⁸^ORCID,Liu Ting-Hui⁹,Huang Po-Yu³,Chuang Min-Hsiang³,Lai Chih-Cheng¹⁰¹¹^ORCID

Affiliation:

1. Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan

2. School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung, Taiwan

3. Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan

4. Divison of General Medicine, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan

5. Center for Integrative Medicine, Chi Mei Medical Center, Tainan, Taiwan

6. Department of Medical Laboratory Sciences and Biotechnology, Fooyin University, Kaohsiung, Taiwan

7. Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan

8. Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

9. Department of Psychiatry, Chi Mei Medical Center, Tainan, Taiwan

10. Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan

11. School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan

Funder

no funding

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14787210.2024.2339398

Reference48 articles.

1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

2. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status

3. World Health Organization. [cited 2023 Oct 7]. Available from: https://covid19.who.int/

4. Clinical characteristics and factors associated with severe COVID-19 in hospitalized children during the SARS-CoV-2 Omicron pandemic in Taiwan

5. How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020–2022